Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This is a single arm dose escalation study of recombinant human keratinocyte growth factor
given to patients undergoing allogeneic bone marrow transplantation who are at high risk for
graft versus host disease (GVHD).